🏛️ Verified NIH Record • Updated 2026-03-24
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies (NCT06395519)
🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: 858 Therapeutics, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- Mayo Clinic — Phoenix, Arizona
- Yale University, Yale Cancer Center — New Haven, Connecticut
- Mayo Clinic — Jacksonville, Florida
- University of Chicago Medical Center — Chicago, Illinois
- Massachusetts General Hospital — Boston, Massachusetts
- Mayo Clinic — Rochester, Minnesota
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Stefanie Spielman Comprehensive Breast Center — Columbus, Ohio
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center — Philadelphia, Pennsylvania
- MD Anderson Cancer Center — Houston, Texas
- START Center for Cancer Care - Mountain Region — Salt Lake City, Utah
- Virginia Cancer Specialists — Fairfax, Virginia
- Fred Hutchinson Cancer Center — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (858) 987-8380
Email: dmccormick@8five8tx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced or Metastatic Solid Tumors
- A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) — Sioux Falls, South Dakota
- A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors — Denver, Colorado
- A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations — San Francisco, California
- Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors — Boston, Massachusetts
- A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors — Birmingham, Alabama
- A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors — Los Angeles, California
Explore by condition: All Advanced or Metastatic Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.